logo
Are collagen shots and supplements really the secret to youthful skin?

Are collagen shots and supplements really the secret to youthful skin?

The Guardian19-07-2025
From high-end aesthetics clinics to the middle aisle of Lidl, collagen is having a moment. Whether it's in the form of fruity shots or powdered supplements, this structural protein is being touted as the secret to youthful skin and glossy hair.
Celebrities are also singing the praises of a collagen-boosting procedure called NeoGen, with the actor Leslie Ash claiming earlier this week that it had 'taken 10 years off her'.
But amid the glowing endorsements and glossy marketing, a fundamental question remains: can anything else really boost collagen – and is it desirable to do so?
Collagens are a group of proteins that provide structural support and mechanical strength to the gel-like extracellular matrix in skin, cartilage and other body tissues. There are various types, each comprising long chains of amino acids that wind together to form strong fibres called fibrils.
Viewed under an electron microscope, these fibrils form a basket-like mesh in young, healthy skin. But as we age, the amount of collagen declines and its structure becomes more cross-linked and fragmented.
'In younger skin, the fibres tend to be longer and more flexible, but in older skin, they're shorter and more rigid, primarily as a result of UV damage,' said Prof John Connelly, who studies skin repair and regeneration at Queen Mary University of London.
Collagen is not the only protein that keeps skin looking youthful. Elastin allows skin to stretch and spring back, while other structural proteins help to organise and stabilise collagen. Long sugar chains known as glycosaminoglycans – including the popular skincare ingredient hyaluronic acid – play a key role in hydrating the tissue. Like collagen, these components degrade and change with age, contributing to sagging, reduced plumpness and wrinkles.
Yet collagen continues to dominate the spotlight. Many skincare products list it as an ingredient but 'these proteins are very large, so they don't easily cross the skin barrier when applied topically', said Prof Tanya Shaw, a spokesperson for the British Skin Foundation and expert in wound healing at King's College London. That said, collagen in creams may help draw moisture to the skin's surface, providing a temporary plumping effect.
Collagen drinks are the latest plot twist. Their aim is to supply the raw materials for fibroblasts, the skin cells responsible for collagen production. There was also evidence that fragments of extracellular matrix proteins might act as signals, stimulating fibroblasts to produce not just collagen but also elastin and hyaluronic acid, said Dr Jonathan Kentley, a consultant dermatologist at the Montrose clinic in London and Chelsea and Westminster hospital.
Most collagen supplements use fragments derived from chicken, fish or pork, which are absorbed through the gut and transported to the skin via the bloodstream. However, many are probably broken down further during digestion and it is unclear whether other dietary proteins would offer similar building blocks, according to Connelly and Shaw.
Even if some fragments do reach the skin, they would be working in a damaged environment. 'If you start to make new collagen, where does it go, and how does it interact with the existing collagen?' said Dr Mike Sherratt, a skin mechanics expert at the University of Manchester. Also, 'if it gets into the bloodstream, it's not only going to affect the skin, but presumably other organs and tissues as well'.
Animal studies offer some support for collagen supplements: radio-labelled collagen fragments have been shown to reach the skin and boost gene activity linked to collagen production in mice. 'Mouse studies have also shown reduced wrinkle formation following UV exposure,' said Kentley.
Some human trials have also reported improved hydration, elasticity, and fewer wrinkles after consuming fish collagen. But most of these were industry-funded and a recent meta-analysis of 23 studies found that only those receiving funding from companies showed significant effects. Kentley said: 'When the studies were separated into high-quality and low-quality studies, the high-quality studies showed no skin benefits. So, these results must be interpreted with extreme caution.'
What about medical procedures such as NeoGen? It uses high-frequency radio waves to covert nitrogen gas into plasma (ionised gas), which delivers controlled heat to deeper layers of the skin. Animal studies suggest this controlled thermal damage alters collagen structure, causing skin tightening, and promotes the shedding of surface layers, improving tone and texture.
'Small clinical studies on patients have also shown an improvement in skin tone and wrinkling,' said Kentley. 'However, as this is a relatively new technology there is relatively little evidence other than a handful of small studies.'
Other procedures such as microneedling also induce tiny, controlled injuries to the skin, triggering a wound healing response, while injectable 'biostimulators' – such as Sculptra – create a foreign body response that stimulates fibroblasts.
While all these procedures have some clinical evidence supporting their ability to stimulate new collagen, the quality is variable and no head-to-head trials have pitted these products and procedures against each other.
Kentley said: 'Given that aesthetic medicine is so highly personalised and each product or procedure will have its own benefits and risks, the best way to know what is right for you is by seeing a qualified physician who is not conflicted by the quest for profit.
'In terms of topical treatments, there are decades of evidence to support the use of tretinoin [a prescription-strength retinoid] to boost collagen production and reduce other signs of skin ageing such as pigmentation.'
Although celebrity endorsements and dramatic before-and-after pictures can be persuasive, it is also worth remembering that these procedures are not a permanent fix for skin ageing – they require continuing treatments, which can be costly. The most effective long-term strategy to protect and preserve your collagen is to minimise UV exposure from an early age, through consistent use of sunscreen.
Sherratt showed me a photo of him during Britain's 1976 heatwave, when he was nine. Unlike the proteins inside our cells that are regularly renewed, he said, type I collagen in the dermis had a half-life of about 15 years and elastin was thought to be meant to last a lifetime. 'These proteins accumulate damage over time. So, it's highly likely that some of the extracellular matrix proteins in my face and forearm still carry damage from that 1976 holiday.'
For those of us who did not faithfully apply sunscreen in our youth, it is worth being realistic about how much even the most advanced treatments can achieve. While they may temporarily firm and smooth the skin, the deeper biological damage has already taken place – and much of it may be irreversible.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Warning issued to patients after using weight-loss jabs
Warning issued to patients after using weight-loss jabs

The Independent

time22 minutes ago

  • The Independent

Warning issued to patients after using weight-loss jabs

Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the pounds again. The National Institute for Health and Care Excellence (Nice), the UK's health watchdog, highlighted research indicating that many individuals regain weight if not adequately supported after ceasing treatment. Nice stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance specifically applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. Over the next three years, approximately 240,000 people deemed to have the "greatest need" are anticipated to receive Mounjaro, also known as tirzepatide, via the NHS. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: ' Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'

Urgent warning over virus dangerous to newborns as cases surge abroad
Urgent warning over virus dangerous to newborns as cases surge abroad

The Independent

time22 minutes ago

  • The Independent

Urgent warning over virus dangerous to newborns as cases surge abroad

Health experts say the UK should brace for a surge in a potentially serious virus following a record number of cases in Australia. NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. In Australia, respiratory syncytial virus (RSV) cases have surged in recent months, and officials have said that cases have been steadily increasing in England since the start of 2025. NHS England has urged pregnant women to get the vaccine, which protects against RSV, in order to protect their newborn babies. The virus is a leading cause of death among babies and the main cause of hospital admissions for children. Kate Brintworth, chief midwifery officer for NHS England, said that while for most adults, RSV 'only causes mild, cold-like symptoms, for older adults and young children, it can lead to serious breathing problems that can end up in hospitalisation'. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab, and NHS England will start inviting people to come forward in the next few weeks. Symptoms of an RSV infection NHS RSV is a common cause of coughs and colds, but some people have a high risk of getting seriously ill from the virus, including babies and adults over the age of 75. In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency published data showing the efficacy of the vaccine. It said that the jab for pregnant women can prevent 72 per cent of hospital admissions for their babies. And the vaccine is 82 per cent effective at preventing hospital admissions for RSV among older adults, UKHSA said.

Wegovy and Mounjaro patients should be monitored for at least a YEAR after stopping drugs, watchdog says
Wegovy and Mounjaro patients should be monitored for at least a YEAR after stopping drugs, watchdog says

Daily Mail​

time22 minutes ago

  • Daily Mail​

Wegovy and Mounjaro patients should be monitored for at least a YEAR after stopping drugs, watchdog says

Patients should be monitored for a year after stopping weight loss jabs to prevent them piling the pounds back on, new guidelines say. The drugs' watchdog is concerned about the number of people regaining weight after coming off the likes of Wegovy and Mounjaro. They must now be offered 'structured advice and follow-up support' to help them maintain healthy lifestyles for the long-term, the National Institute for Health and Care Excellence (Nice) said. Its guidance applies to everyone who obtains the treatments through the NHS in England and Wales - and healthcare workers are expected to comply immediately. An estimated 1.5 million people are taking weight loss jabs in the UK but the vast majority are paying around £200 a month to obtain them privately. Some 240,000 people with 'greatest need' are set to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice tells health providers they should monitor NHS patients for at least a year after they complete treatment and offer extra tailored support if needed. It says: 'This could include practical advice from programmes like NHS Better Health on changing daily habits or making adjustments at home or work to avoid slipping back.' The guidance emphasises the need to establish 'long-term behavioural habits' and suggests the use of regular check-ins, community support groups, local activity classes, and help developing 'sustainable routines'. Studies found people injected with semaglutide, the active ingredient in Wegovy and Ozempic, lost 14 per cent of their body weight over 72 weeks. And those taking Mounjaro, known as the 'king kong' of weight-loss jabs, lost 20 per cent of their body weight over the the same period. But research also shows that many people regain weight after stopping treatment if they do not get the right help. Health officials say this can negatively affect their physical and mental health. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' In England, 29 per cent of adults are obese and 64 per cent or overweight or obese. Obesity places extra pressure on the NHS and wider economy by increasing the risk type 2 diabetes, heart disease, cancer and musculoskeletal problems. Estimates suggest obesity costs the NHS £11.4 billion a year, with a wider economic impact of £74.3 billion due to lost productivity, unemployment and increased demand for social care. Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Professor Kamila Hawthorne, chair of the Royal College of GPs, said: 'There is no one-size fits all approach to tackling obesity - what works for one patient will likely not work for another, and as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. 'As such, this is important and sensible guidance from NICE. 'As a College we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet', and ensuring access to sufficient 'wraparound" services – particularly for when patients come off their medication – will be key to optimal health outcomes. 'We need to see a greater focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store